{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:58:38Z","timestamp":1790013518196,"version":"4.0.1"},"reference-count":88,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T00:00:00Z","timestamp":1624406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2016\/21\/B\/NZ6\/02028"],"award-info":[{"award-number":["2016\/21\/B\/NZ6\/02028"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2016\/23\/D\/NZ1\/02611"],"award-info":[{"award-number":["2016\/23\/D\/NZ1\/02611"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Pseudomonas aeruginosa is an opportunistic human pathogen that has become a nosocomial health problem worldwide. The pathogen has multiple drug removal and virulence secretion systems, is resistant to many antibiotics, and there is no commercial vaccine against it. Yersinia pestis is a zoonotic pathogen that is on the Select Agents list. The bacterium is the deadliest pathogen known to humans and antibiotic-resistant strains are appearing naturally. There is no commercial vaccine against the pathogen, either. In the current work, novel compounds based on metallacarborane cage were studied on strains of Pseudomonas aeruginosa and a Yersinia pestis substitute, Yersinia enterocolitica. The representative compounds had IC50 values below 10 \u00b5M against Y. enterocolitica and values of 20\u201350 \u03bcM against P. aeruginosa. Artificial generation of compound-resistant Y. enterocolitica suggested a common mechanism for drug resistance, the first reported in the literature, and suggested N-linked metallacarboranes as impervious to cellular mechanisms of resistance generation. SEM analysis of the compound-resistant strains showed that the compounds had a predominantly bacteriostatic effect and blocked bacterial cell division in Y. enterocolitica. The compounds could be a starting point towards novel anti-Yersinia drugs and the strategy presented here proposes a mechanism to bypass any future drug resistance in bacteria.<\/jats:p>","DOI":"10.3390\/ijms22136762","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T11:28:41Z","timestamp":1624447721000},"page":"6762","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Metallacarborane Derivatives Effective against Pseudomonas aeruginosa and Yersinia enterocolitica"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9354-8184","authenticated-orcid":false,"given":"Wieslaw","family":"Swietnicki","sequence":"first","affiliation":[{"name":"Laboratory of Medical Microbiology, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Weigla 12, 53-114 Wroc\u0142aw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waldemar","family":"Goldeman","sequence":"additional","affiliation":[{"name":"Department of Organic and Medicinal Chemistry, Faculty of Chemistry, Wroc\u0142aw University of Science and Technology, Wybrzeze Wyspianskiego 27, 50-370 Wroc\u0142aw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8866-7149","authenticated-orcid":false,"given":"Mateusz","family":"Psurski","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Anticancer Therapy, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Weigla 12, 53-114 Wroc\u0142aw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Nasulewicz-Goldeman","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Anticancer Therapy, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Weigla 12, 53-114 Wroc\u0142aw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2203-1636","authenticated-orcid":false,"given":"Anna","family":"Boguszewska-Czubara","sequence":"additional","affiliation":[{"name":"Department of Medical Chemistry, Medical University of Lublin, 4A Chodzki Street, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Drab","sequence":"additional","affiliation":[{"name":"USI, Unit of Nanostructural Biointeractions, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Weigla 12, 53-114 Wroc\u0142aw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Sycz","sequence":"additional","affiliation":[{"name":"Laboratory of Medical Microbiology, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Weigla 12, 53-114 Wroc\u0142aw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9995-3260","authenticated-orcid":false,"given":"Tomasz M.","family":"Goszczy\u0144ski","sequence":"additional","affiliation":[{"name":"Laboratory of Biomedical Chemistry, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Weigla 12, 53-114 Wroc\u0142aw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3389\/fmicb.2019.00539","article-title":"Emerging Strategies to Combat ESKAPE Pathogens in the Era of Antimicrobial Resistance: A Review","volume":"10","author":"Mulani","year":"2019","journal-title":"Front. Microbiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1586\/eri.13.12","article-title":"Clinical relevance of the ESKAPE pathogens","volume":"11","author":"Pendleton","year":"2013","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ijantimicag.2009.06.007","article-title":"Efflux pump inhibitors reduce the invasiveness of Pseudomonas aeruginosa","volume":"34","author":"Hirakata","year":"2009","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.tips.2016.05.011","article-title":"Targeting the Type Three Secretion System in Pseudomonas aeruginosa","volume":"37","author":"Anantharajah","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.3389\/fmicb.2019.01218","article-title":"A Type VI Secretion System Trans-Kingdom Effector Is Required for the Delivery of a Novel Antibacterial Toxin in Pseudomonas aeruginosa","volume":"10","author":"Berni","year":"2019","journal-title":"Front. Microbiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.celrep.2019.08.094","article-title":"The Pseudomonas aeruginosa T6SS Delivers a Periplasmic Toxin that Disrupts Bacterial Cell Morphology","volume":"29","author":"Wood","year":"2019","journal-title":"Cell Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41564-018-0191-x","article-title":"The type VI secretion system deploys antifungal effectors against microbial competitors","volume":"3","author":"Trunk","year":"2018","journal-title":"Nat. Microbiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.chom.2016.12.004","article-title":"The Bacterial T6SS Effector EvpP Prevents NLRP3 Inflammasome Activation by Inhibiting the Ca(2+)-Dependent MAPK-Jnk Pathway","volume":"21","author":"Chen","year":"2017","journal-title":"Cell Host Microbe"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1189\/jlb.4MR0716-330R","article-title":"Bacterial secretion systems and regulation of inflammasome activation","volume":"101","author":"Ratner","year":"2017","journal-title":"J. Leukoc. Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1167\/iovs.02-1302","article-title":"Contribution of ExsA-regulated factors to corneal infection by cytotoxic and invasive Pseudomonas aeruginosa in a murine scarification model","volume":"44","author":"Lee","year":"2003","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_11","first-page":"345","article-title":"Immunization of cystic fibrosis patients with a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine","volume":"98","author":"Cryz","year":"1997","journal-title":"Behring Inst. Mitt."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5689709","DOI":"10.1155\/2017\/5689709","article-title":"Immunization with Bivalent Flagellin Protects Mice against Fatal Pseudomonas aeruginosa Pneumonia","volume":"2017","author":"Behrouz","year":"2017","journal-title":"J. Immunol. Res."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Hegerle, N., Choi, M., Sinclair, J., Amin, M.N., Ollivault-Shiflett, M., Curtis, B., Laufer, R.S., Shridhar, S., Brammer, J., and Toapanta, F.R. (2018). Development of a broad spectrum glycoconjugate vaccine to prevent wound and disseminated infections with Klebsiella pneumoniae and Pseudomonas aeruginosa. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0203143"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"103697","DOI":"10.1016\/j.micpath.2019.103697","article-title":"A trivalent vaccine consisting of \u201cflagellin A+B and pilin\u201d protects against Pseudomonas aeruginosa infection in a murine burn model","volume":"138","author":"Hashemi","year":"2020","journal-title":"Microb. Pathog."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"11020","DOI":"10.1073\/pnas.0702403104","article-title":"A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients","volume":"104","author":"Doring","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/1348-0421.12291","article-title":"Salmonella Typhimurium strain expressing OprF-OprI protects mice against fatal infection by Pseudomonas aeruginosa","volume":"59","author":"Zhang","year":"2015","journal-title":"Microbiol. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.2147\/IDR.S244081","article-title":"Protective Efficacy of the OprF\/OprI\/PcrV Recombinant Chimeric Protein Against Pseudomonas aeruginosa in the Burned BALB\/c Mouse Model","volume":"13","author":"Fakoor","year":"2020","journal-title":"Infect. Drug Resist."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13054-020-2792-z","article-title":"Efficacy, immunogenicity, and safety of IC43 recombinant Pseudomonas aeruginosa vaccine in mechanically ventilated intensive care patients-a randomized clinical trial","volume":"24","author":"Adlbrecht","year":"2020","journal-title":"Crit. Care"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ijbiomac.2020.05.057","article-title":"Oligomerization of IC43 resulted in improved immunogenicity and protective efficacy against Pseudomonas aeruginosa lung infection","volume":"159","author":"Jing","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5908","DOI":"10.1128\/IAI.69.9.5908-5910.2001","article-title":"PcrV immunization enhances survival of burned Pseudomonas aeruginosa-infected mice","volume":"69","author":"Holder","year":"2001","journal-title":"Infect. Immun."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"781","DOI":"10.3389\/fimmu.2019.00781","article-title":"Rational Design of a Chimeric Derivative of PcrV as a Subunit Vaccine Against Pseudomonas aeruginosa","volume":"10","author":"Wan","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/1348-0421.12467","article-title":"Efficacy comparison of adjuvants in PcrV vaccine against Pseudomonas aeruginosa pneumonia","volume":"61","author":"Hamaoka","year":"2017","journal-title":"Microbiol. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Aguilera-Herce, J., Garcia-Quintanilla, M., Romero-Flores, R., McConnell, M.J., and Ramos-Morales, F. (2019). A Live Salmonella Vaccine Delivering PcrV through the Type III Secretion System Protects against Pseudomonas aeruginosa. mSphere, 4.","DOI":"10.1128\/mSphere.00116-19"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/1348-0421.12658","article-title":"The protective effects of nasal PcrV-CpG oligonucleotide vaccination against Pseudomonas aeruginosa pneumonia","volume":"62","author":"Naito","year":"2018","journal-title":"Microbiol. Immunol."},{"key":"ref_25","first-page":"15","article-title":"Immunization with 3-oxododecanoyl-L-homoserine lactone-r-PcrV conjugate enhances survival of mice against lethal burn infections caused by Pseudomonas aeruginosa","volume":"15","author":"Golpasha","year":"2015","journal-title":"Bosn. J. Basic Med. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/7391","article-title":"Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury","volume":"5","author":"Sawa","year":"1999","journal-title":"Nat. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"583008","DOI":"10.3389\/fimmu.2020.583008","article-title":"Development of a Broadly Protective, Self-Adjuvanting Subunit Vaccine to Prevent Infections by Pseudomonas aeruginosa","volume":"11","author":"Das","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"6926","DOI":"10.1016\/j.vaccine.2018.10.010","article-title":"PLGA-encapsulation of the Pseudomonas aeruginosa PopB vaccine antigen improves Th17 responses and confers protection against experimental acute pneumonia","volume":"36","author":"Schaefers","year":"2018","journal-title":"Vaccine"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1248\/bpb.b19-01052","article-title":"Construction of Genomic Library and High-Throughput Screening of Pseudomonas aeruginosa Novel Antigens for Potential Vaccines","volume":"43","author":"Xu","year":"2020","journal-title":"Biol. Pharm. Bull."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.vaccine.2018.01.034","article-title":"Immunization with Pseudomonas aeruginosa outer membrane vesicles stimulates protective immunity in mice","volume":"36","author":"Zhang","year":"2018","journal-title":"Vaccine"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1097\/CCM.0b013e31825334f6","article-title":"Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: A randomized, double-blind, placebo-controlled trial","volume":"40","author":"Francois","year":"2012","journal-title":"Crit. Care Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.molimm.2019.10.005","article-title":"Anti-PcrV IgY antibodies protect against Pseudomonas aeruginosa infection in both acute pneumonia and burn wound models","volume":"116","author":"Ranjbar","year":"2019","journal-title":"Mol. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"5810767","DOI":"10.1155\/2018\/5810767","article-title":"Small Molecule Inhibitor of Type Three Secretion System Belonging to a Class 2,4-disubstituted-4H-[1,3,4]-thiadiazine-5-ones Improves Survival and Decreases Bacterial Loads in an Airway Pseudomonas aeruginosa Infection in Mice","volume":"2018","author":"Sheremet","year":"2018","journal-title":"Biomed. Res. Int."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/ja.2017.64","article-title":"The salicylidene acylhydrazide INP0341 attenuates Pseudomonas aeruginosa virulence in vitro and in vivo","volume":"70","author":"Uusitalo","year":"2017","journal-title":"J. Antibiot."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1021\/acscentsci.9b00452","article-title":"Tanshinones: First-in-Class Inhibitors of the Biogenesis of the Type 3 Secretion System Needle of Pseudomonas aeruginosa for Antibiotic Therapy","volume":"5","author":"Feng","year":"2019","journal-title":"ACS Cent. Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3389\/fcimb.2019.00250","article-title":"Development, Optimization, and Validation of a High Throughput Screening Assay for Identification of Tat and Type II Secretion Inhibitors of Pseudomonas aeruginosa","volume":"9","author":"Massai","year":"2019","journal-title":"Front. Cell Infect. Microbiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.bbrc.2019.04.055","article-title":"Identification of a potent inhibitor of type II secretion system from Pseudomonas aeruginosa","volume":"513","author":"Swietnicki","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1128\/IAI.66.2.521-527.1998","article-title":"Analysis of the Yersinia pestis V protein for the presence of linear antibody epitopes","volume":"66","author":"Pullen","year":"1998","journal-title":"Infect. Immun."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ijantimicag.2017.09.015","article-title":"Plasmid-mediated doxycycline resistance in a Yersinia pestis strain isolated from a rat","volume":"51","author":"Cabanel","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_40","first-page":"37","article-title":"[Sensitivity of Yersinia pestis to antibiotics: 277 strains isolated in Madagascar between 1926 and 1989]","volume":"56","author":"Rasoamanana","year":"1989","journal-title":"Arch. Inst. Pasteur Madag."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1056\/NEJM199709043371004","article-title":"Multidrug resistance in Yersinia pestis mediated by a transferable plasmid","volume":"337","author":"Galimand","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Atkinson, S., and Williams, P. (2016). Yersinia virulence factors\u2014A sophisticated arsenal for combating host defences. F1000Res, 5.","DOI":"10.12688\/f1000research.8466.1"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Swietnicki, W., Carmany, D., Retford, M., Guelta, M., Dorsey, R., Bozue, J., Lee, M.S., and Olson, M.A. (2011). Identification of small-molecule inhibitors of Yersinia pestis Type III secretion system YscN ATPase. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0019716"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1128\/AAC.00670-08","article-title":"Targeting type III secretion in Yersinia pestis","volume":"53","author":"Pan","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_45","first-page":"49","article-title":"Design of small molecule inhibitors of type III secretion system ATPase EscN from enteropathogenic Escherichia coli","volume":"64","author":"Bzdzion","year":"2017","journal-title":"Acta Biochim. Pol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1699-0463.1993.tb00130.x","article-title":"Experimental Yersinia enterocolitica infection in rodents: A model for human yersiniosis","volume":"101","author":"Heesemann","year":"1993","journal-title":"APMIS"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4034","DOI":"10.1128\/IAI.00606-12","article-title":"Kinetics of innate immune response to Yersinia pestis after intradermal infection in a mouse model","volume":"80","author":"Bosio","year":"2012","journal-title":"Infect. Immun."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ccc.2007.12.004","article-title":"Current therapies for Pseudomonas aeruginosa","volume":"24","author":"Giamarellou","year":"2008","journal-title":"Crit. Care Clin."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1128\/AAC.01481-10","article-title":"In vitro efficacy of antibiotics commonly used to treat human plague against intracellular Yersinia pestis","volume":"55","author":"Wendte","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Kakoullis, L., Papachristodoulou, E., Chra, P., and Panos, G. (2021). Mechanisms of Antibiotic Resistance in Important Gram-Positive and Gram-Negative Pathogens and Novel Antibiotic Solutions. Antibiotics, 10.","DOI":"10.3390\/antibiotics10040415"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.4155\/fmc.09.71","article-title":"Therapeutic potential of boron-containing compounds","volume":"1","author":"Baker","year":"2009","journal-title":"Future Med. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/cmdc.201700788","article-title":"Phenylboronic Acid Derivatives as Validated Leads Active in Clinical Strains Overexpressing KPC-2: A Step against Bacterial Resistance","volume":"13","author":"Celenza","year":"2018","journal-title":"ChemMedChem"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"8544","DOI":"10.1021\/acs.jmedchem.9b00911","article-title":"Bicyclic Boronate VNRX-5133 Inhibits Metallo- and Serine-beta-Lactamases","volume":"62","author":"Krajnc","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Parkova, A., Lucic, A., Krajnc, A., Brem, J., Calvopina, K., Langley, G.W., McDonough, M.A., Trapencieris, P., and Schofield, C.J. (2020). Broad Spectrum beta-Lactamase Inhibition by a Thioether Substituted Bicyclic Boronate. ACS Infect. Dis.","DOI":"10.1021\/acsinfecdis.9b00330"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1128\/AAC.06099-11","article-title":"Crystal structures of KPC-2 beta-lactamase in complex with 3-nitrophenyl boronic acid and the penam sulfone PSR-3-226","volume":"56","author":"Ke","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e1701388","DOI":"10.1002\/adhm.201701388","article-title":"Phenylboronic Acid Functionalized Polycarbonate Hydrogels for Controlled Release of Polymyxin B in Pseudomonas aeruginosa Infected Burn Wounds","volume":"7","author":"Obuobi","year":"2018","journal-title":"Adv. Healthc. Mater."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Purnapatre, K.P., Rao, M., Pandya, M., Khanna, A., Chaira, T., Bambal, R., Upadhyay, D.J., and Masuda, N. (2018). In Vitro and In Vivo Activities of DS86760016, a Novel Leucyl-tRNA Synthetase Inhibitor for Gram-Negative Pathogens. Antimicrob. Agents Chemother., 62.","DOI":"10.1128\/AAC.01987-17"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3283","DOI":"10.1021\/jm0701977","article-title":"Novel boron-containing, nonclassical antifolates: Synthesis and preliminary biological and structural evaluation","volume":"50","author":"Reynolds","year":"2007","journal-title":"J. Med. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"10364","DOI":"10.1002\/chem.201801602","article-title":"The closo-Dodecaborate Dianion Fused with Oxazoles Provides 3D Diboraheterocycles with Selective Antimicrobial Activity","volume":"24","author":"Sun","year":"2018","journal-title":"Chemistry"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Gozzi, M., Schwarze, B., and Hey-Hawkins, E. (2021). Preparing (Metalla)carboranes for Nanomedicine. ChemMedChem.","DOI":"10.1002\/cmdc.202000983"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/14712598.2018.1473369","article-title":"Icosahedral boron clusters as modifying entities for biomolecules","volume":"18","author":"Goszczynski","year":"2018","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"7738","DOI":"10.1021\/acs.jmedchem.5b01932","article-title":"Challenges and Opportunities for the Application of Boron Clusters in Drug Design","volume":"59","author":"Lesnikowski","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jorganchem.2013.07.006","article-title":"Investigations on antimicrobial activity of cobaltabisdicarbollides","volume":"747","author":"Popova","year":"2013","journal-title":"J. Organomet. Chem."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1021\/acs.organomet.7b00426","article-title":"A Highly Potent Antibacterial Agent Targeting Methicillin-Resistant Staphylococcus aureus Based on Cobalt Bis(1,2-Dicarbollide) Alkoxy Derivative","volume":"36","author":"Zheng","year":"2017","journal-title":"Organometallics"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1021\/jm00144a024","article-title":"Synthesis and in vitro antimicrobial property of o-carborane derivatives","volume":"24","author":"Totani","year":"1981","journal-title":"J. Med. Chem."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jorganchem.2016.10.037","article-title":"Preparation, characterization, and the selective antimicrobial activity of N-alkylammonium 8-diethyleneglycol cobalt bis-dicarbollide derivatives","volume":"827","author":"Kvasnickova","year":"2017","journal-title":"J. Organomet. Chem."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Vankova, E., Lokocova, K., Matatkova, O., Krizova, I., Masak, J., Gruner, B., Kaule, P., Cermak, J., and Sicha, V. (2019). Cobalt bis-dicarbollide and its ammonium derivatives are effective antimicrobial and antibiofilm agents. J. Organomet. Chem., 899.","DOI":"10.1016\/j.jorganchem.2019.120891"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"7804","DOI":"10.1038\/srep07804","article-title":"Biological interaction of living cells with COSAN-based synthetic vesicles","volume":"5","author":"Tarres","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1135\/cccc19841492","article-title":"A [8,8\u2032-Mu-I-3-Co(1,2-C2b9h10)2] Metallacarborane Complex with a Iodonium Bridge\u2014Evidence for a Bromonium Analog","volume":"49","author":"Plesek","year":"1984","journal-title":"Collect. Czechoslov. Chem. Commun."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jorganchem.2014.07.005","article-title":"Novel alkoxy derivatives of cobalt bis(1,2-dicarbollide)","volume":"769","author":"Kosenko","year":"2014","journal-title":"J. Organomet. Chem."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"5366","DOI":"10.1021\/om100385m","article-title":"C-H Bond Activation of Arenes by [8,8\u2032-mu-I-3,3\u2032-Co(1,2-C2B9H10)(2)] in the Presence of Sterically Hindered Lewis Bases","volume":"29","author":"Bregadze","year":"2010","journal-title":"Organometallics"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s12011-016-0637-z","article-title":"Antibacterial and Antibiofilm Effects of Boron on Different Bacteria","volume":"173","author":"Sayin","year":"2016","journal-title":"Biol. Trace Elem. Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.biomaterials.2012.10.069","article-title":"Antimicrobial activity of a ferrocene-substituted carborane derivative targeting multidrug-resistant infection","volume":"34","author":"Li","year":"2013","journal-title":"Biomaterials"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0968-0896(01)00300-5","article-title":"Syntheses and preliminary biological studies of four meso-Tetra[(nido-carboranylmethyl)phenyl]porphyrins","volume":"10","author":"Vicente","year":"2002","journal-title":"Bioorg. Med. Chem."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"15394","DOI":"10.1073\/pnas.0507577102","article-title":"From nonpeptide toward noncarbon protease inhibitors: Metallacarboranes as specific and potent inhibitors of HIV protease","volume":"102","author":"Cigler","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"9560","DOI":"10.1021\/acs.jmedchem.9b00945","article-title":"Metallacarborane Sulfamides: Unconventional, Specific, and Highly Selective Inhibitors of Carbonic Anhydrase IX","volume":"62","author":"Gruner","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Vinas, C., Fuentes, I., Garcia-Mendiola, T., Sato, S., Pita, M., Nakamura, H., Lorenzo, E., Teixidor, F., and Marques, F. (2018). Metallacarboranes on the road to anticancer therapies: Cellular uptake, DNA interaction and biological evaluation of cobaltabisdicarbollide ([COSAN]-). Chemistry.","DOI":"10.1002\/chem.201886564"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"213684","DOI":"10.1016\/j.ccr.2020.213684","article-title":"Boron cluster compounds as new chemical leads for antimicrobial therapy","volume":"431","author":"Fink","year":"2021","journal-title":"Coord. Chem. Rev."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"7934","DOI":"10.1021\/acsnano.6b03862","article-title":"Antimicrobial Cluster Bombs: Silver Nanoclusters Packed with Daptomycin","volume":"10","author":"Zheng","year":"2016","journal-title":"ACS Nano"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/nnano.2012.91","article-title":"Vanadium pentoxide nanoparticles mimic vanadium haloperoxidases and thwart biofilm formation","volume":"7","author":"Natalio","year":"2012","journal-title":"Nat. Nanotechnol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1016\/j.biomaterials.2011.11.057","article-title":"The molecular mechanism of action of bactericidal gold nanoparticles on Escherichia coli","volume":"33","author":"Cui","year":"2012","journal-title":"Biomaterials"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/jnci\/82.13.1107","article-title":"New colorimetric cytotoxicity assay for anticancer-drug screening","volume":"82","author":"Skehan","year":"1990","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1002\/chem.200304970","article-title":"Relevance of the electronegativity of boron in eta(5)-coordinating ligands: Regioselective monoalkylation and monoarylation in cobaltabisdicarbollide [3,3\u2032-Co(1,2-C2B9H11)(2)](-) clusters","volume":"9","author":"Rojo","year":"2003","journal-title":"Chem. Eur. J."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1021\/om030412r","article-title":"Methylation and demethylation in cobaltabis(dicarbollide) derivatives","volume":"22","author":"Rojo","year":"2003","journal-title":"Organometallics"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0277-5387(00)81604-6","article-title":"B-Halogen derivatives of the bis(1,2-dicarbollyl)cobalt(III) anion","volume":"1","author":"Rajec","year":"1982","journal-title":"Polyhedron"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1021\/acs.oprd.5b00417","article-title":"NMR Chemical Shifts of Trace Impurities: Industrially Preferred Solvents Used in Process and Green Chemistry","volume":"20","author":"Babij","year":"2016","journal-title":"Org. Process. Res. Dev."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"7512","DOI":"10.1021\/jo971176v","article-title":"NMR chemical shifts of common laboratory solvents as trace impurities","volume":"62","author":"Gottlieb","year":"1997","journal-title":"J. Org. Chem."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.tibtech.2018.03.002","article-title":"Phage Aggregation-Dispersion by Ions: Striving beyond Antibacterial Therapy","volume":"36","author":"Drab","year":"2018","journal-title":"Trends Biotechnol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/13\/6762\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:22:19Z","timestamp":1760163739000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/13\/6762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,23]]},"references-count":88,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["ijms22136762"],"URL":"https:\/\/doi.org\/10.3390\/ijms22136762","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,23]]}}}